CEL-SCI Corporation (CVM) - 10-Q Summary
Business Context and Reporting Period
Company: CEL-SCI Corporation (CEL-SCI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: CEL-SCI is a late clinical-stage biotechnology company focused on developing Multikine, an investigational immunotherapy for head and neck cancer, and L.E.A.P.S. technology for rheumatoid arthritis. The company has not generated any revenue to date and relies on capital raises to fund operations and clinical trials.
Key Financial Metrics
| Metric | Nine Months Ended June 30, 2026 | Nine Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(16,602,722) | $(19,310,155) |
| Net Loss Per Share (Basic & Diluted) | $(1.76) | $(6.34) |
| Cash and Cash Equivalents (End of Period) | $6,527,381 | $1,792,856 |
| Net Cash Used in Operating Activities | $(12,075,720) | $(12,449,214) |
| Total Assets | $21,355,416 | $28,155,748 |
| Total Liabilities | $10,399,628 | $12,198,663 |
| Stockholders' Equity | $10,955,788 | $15,957,085 |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $2.7 million (14%) compared to the prior nine-month period, primarily due to reduced operating expenses.
- Operating Expenses: Total operating expenses declined from $18.8 million to $16.3 million.
- R&D Expenses: Decreased by $1.1 million (9%), driven by lower clinical trial costs ($0.4M reduction) and supplies/materials ($0.9M reduction).
- G&A Expenses: Decreased by $1.4 million (22%), largely due to a $1.1 million reduction in public and investor relations costs.
- Liquidity Position: Cash balances increased significantly from $1.8 million to $6.5 million, supported by equity financings totaling approximately $9.7 million in gross proceeds during the period.
- Share Count: Weighted average shares outstanding increased significantly (from ~3.0M to ~9.4M) due to equity issuances and a reverse stock split adjustment in the prior year.
Outlook, Risks, and Management Commentary
- Going Concern Warning: The filing explicitly states there is "substantial doubt" about the company's ability to continue as a going concern due to recurring losses and future liquidity needs. Continued operations depend on raising additional capital.
- Capital Requirements: The estimated cost for the upcoming confirmatory registration study for Multikine is $30-$35 million. The company plans to raise funds through corporate partnerships, debt, or equity financings.
- Clinical Progress: Management highlights strong Phase III data for Multikine in a specific target population (low PD-L1 expression), showing a 73% 5-year survival rate vs. 45% for control. The company is preparing for a 212-patient confirmatory registration study.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, due to material weaknesses previously disclosed in the 10-K.
- Unusual Items: The company issued shares to settle clinical development costs and to consultants. A significant portion of R&D expenses ($2.8M) consists of non-cash depreciation and amortization related to finance leases.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $6.5M cash balance against the estimated $30-$35M cost of the confirmatory study and ongoing burn rate.
- Financing Terms: Review the terms of recent equity issuances (May/June 2026) for dilution impact and any attached warrants or rights.
- Lease Obligations: Assess the impact of significant finance lease liabilities (~$6.3M total) and the requirement to maintain minimum cash balances to avoid forfeiting deposits.
- Regulatory Pathway: Confirm the FDA's specific requirements for the confirmatory study and the timeline for enrollment.
- Internal Controls: Monitor remediation efforts regarding the material weaknesses in internal controls over financial reporting.